Biomarker ID | 1520 |
PMID | 25168616 |
Year | 2014 |
Biomarker | PCA3 |
Biomarker Basis | Concentration Based (ng/mL) |
Biomolecule | Protein |
Source | Serum |
Subjects | Humans |
Regulation | Upregulated in Prostate Cancer |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways include: Proteins Involved in Prostate Cancer |
Experiment | Prostate Cancer Vs No Cancer |
Type of Biomarker | Diagnostic |
Cohort | 708 men were included in the study. 589 with No cancer and 119 with Prostate cancer were chosen. In the range PSA >3 ng/ml, there were total of 202 patients. 162 did not have cancer and 40 did |
Senstivity | NA |
Specificity | NA |
AUC | PSA > 3ng/ml Range: 0.62 (95% CI: 0.52–0.73);Full Cohort: 0.63 (95% CI: 0.58–0.69) |
Accuracy | NA |
Level Of Significance | PSA >3ng/ml: p=0.01; All Patients: p<0.01 |
Method Used | NA |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |